CH676665A5 - - Google Patents

Download PDF

Info

Publication number
CH676665A5
CH676665A5 CH4758/88A CH475888A CH676665A5 CH 676665 A5 CH676665 A5 CH 676665A5 CH 4758/88 A CH4758/88 A CH 4758/88A CH 475888 A CH475888 A CH 475888A CH 676665 A5 CH676665 A5 CH 676665A5
Authority
CH
Switzerland
Prior art keywords
cyclodextrin
compound
hydrochloride salt
solution
formulation according
Prior art date
Application number
CH4758/88A
Other languages
German (de)
English (en)
Inventor
Harry Finch
Anthony John Phillips
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878729823A external-priority patent/GB8729823D0/en
Priority claimed from GB888804422A external-priority patent/GB8804422D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CH676665A5 publication Critical patent/CH676665A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CH4758/88A 1987-12-22 1988-12-21 CH676665A5 (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878729823A GB8729823D0 (en) 1987-12-22 1987-12-22 Complexes
GB888804422A GB8804422D0 (en) 1988-02-25 1988-02-25 Complexes

Publications (1)

Publication Number Publication Date
CH676665A5 true CH676665A5 (enrdf_load_stackoverflow) 1991-02-28

Family

ID=26293226

Family Applications (1)

Application Number Title Priority Date Filing Date
CH4758/88A CH676665A5 (enrdf_load_stackoverflow) 1987-12-22 1988-12-21

Country Status (29)

Country Link
JP (1) JPH02210A (enrdf_load_stackoverflow)
KR (1) KR890009402A (enrdf_load_stackoverflow)
CN (1) CN1034132A (enrdf_load_stackoverflow)
AT (1) AT395943B (enrdf_load_stackoverflow)
AU (1) AU615245B2 (enrdf_load_stackoverflow)
BE (1) BE1001704A3 (enrdf_load_stackoverflow)
CA (1) CA1328078C (enrdf_load_stackoverflow)
CH (1) CH676665A5 (enrdf_load_stackoverflow)
DE (1) DE3843059A1 (enrdf_load_stackoverflow)
DK (1) DK712888A (enrdf_load_stackoverflow)
ES (1) ES2011727A6 (enrdf_load_stackoverflow)
FI (1) FI885920A7 (enrdf_load_stackoverflow)
FR (1) FR2624731B1 (enrdf_load_stackoverflow)
GB (1) GB2211737B (enrdf_load_stackoverflow)
GR (1) GR880100854A (enrdf_load_stackoverflow)
HU (1) HU204700B (enrdf_load_stackoverflow)
IE (1) IE61995B1 (enrdf_load_stackoverflow)
IL (1) IL88764A0 (enrdf_load_stackoverflow)
IT (1) IT1224835B (enrdf_load_stackoverflow)
LU (1) LU87411A1 (enrdf_load_stackoverflow)
MY (1) MY103952A (enrdf_load_stackoverflow)
NL (1) NL8803126A (enrdf_load_stackoverflow)
NO (1) NO885689L (enrdf_load_stackoverflow)
NZ (1) NZ227446A (enrdf_load_stackoverflow)
PH (1) PH24982A (enrdf_load_stackoverflow)
PL (1) PL276595A1 (enrdf_load_stackoverflow)
PT (1) PT89301B (enrdf_load_stackoverflow)
SE (1) SE502288C2 (enrdf_load_stackoverflow)
ZW (1) ZW18088A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814725D0 (en) * 1988-06-21 1988-07-27 Glaxo Group Ltd Medicaments
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
KR100825736B1 (ko) * 2005-12-07 2008-04-29 한국전자통신연구원 무선 xml 전자 서명 서비스 제공 장치 및 그 방법
KR100832740B1 (ko) * 2007-01-17 2008-05-27 한국과학기술원 분지쇄 아미노산 생성능이 개선된 변이 미생물 및 이를이용한 분지쇄 아미노산의 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (enrdf_load_stackoverflow) * 1970-06-10 1975-02-04
JPS5443569B2 (enrdf_load_stackoverflow) * 1972-07-05 1979-12-20
HU181703B (en) * 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS57183772A (en) * 1981-04-29 1982-11-12 Glaxo Group Ltd Aminocyclopentanol acids and esters, manufacture and medicinal composition
JPS58116423A (ja) * 1981-12-28 1983-07-11 Sumitomo Chem Co Ltd メタノプロスタサイクリン製剤組成物
JPS58192821A (ja) * 1982-04-30 1983-11-10 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患の治療剤
JPS5946228A (ja) * 1982-09-08 1984-03-15 Zeria Shinyaku Kogyo Kk 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
JPS5973576A (ja) * 1982-09-16 1984-04-25 グラクソ・グル−プ・リミテツド ピペリジニルシクロペンタノ−ルヘプテン酸塩
GB2127406B (en) * 1982-09-16 1986-03-05 Glaxo Group Ltd Piperidinlycyclopentanolheptenoic acid salt
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60150039A (ja) * 1984-01-17 1985-08-07 Minolta Camera Co Ltd 水陸両用固定焦点カメラ
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物

Also Published As

Publication number Publication date
AU2735688A (en) 1989-06-22
ATA313088A (de) 1992-09-15
DK712888D0 (da) 1988-12-21
FR2624731A1 (fr) 1989-06-23
LU87411A1 (fr) 1989-07-07
MY103952A (en) 1993-10-30
AT395943B (de) 1993-04-26
IE883820L (en) 1989-06-22
HUT50040A (en) 1989-12-28
GB2211737B (en) 1991-12-11
CA1328078C (en) 1994-03-29
DK712888A (da) 1989-06-23
GB8829793D0 (en) 1989-02-15
FI885920L (fi) 1989-06-23
SE8804607L (sv) 1989-06-23
JPH02210A (ja) 1990-01-05
NL8803126A (nl) 1989-07-17
SE502288C2 (sv) 1995-09-25
PH24982A (en) 1990-12-26
SE8804607D0 (sv) 1988-12-21
BE1001704A3 (fr) 1990-02-13
IL88764A0 (en) 1989-07-31
AU615245B2 (en) 1991-09-26
PT89301B (pt) 1995-07-03
IE61995B1 (en) 1994-12-14
ES2011727A6 (es) 1990-02-01
CN1034132A (zh) 1989-07-26
NO885689D0 (no) 1988-12-21
ZW18088A1 (en) 1989-07-26
DE3843059A1 (de) 1989-07-13
PL276595A1 (en) 1989-08-21
IT8848702A0 (it) 1988-12-21
PT89301A (pt) 1990-06-29
FI885920A7 (fi) 1989-06-23
KR890009402A (ko) 1989-08-01
IT1224835B (it) 1990-10-24
GR880100854A (el) 1994-03-31
NO885689L (no) 1989-06-23
GB2211737A (en) 1989-07-12
NZ227446A (en) 1991-08-27
HU204700B (en) 1992-02-28
FR2624731B1 (fr) 1992-10-23

Similar Documents

Publication Publication Date Title
DE69330690T2 (de) Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
DE69222950T2 (de) Darmlösliche oral verabreichbare arzneimittel welche säurelabile verbindungen enthalten
DE69231457T2 (de) Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
DE3031710C2 (de) Salze von (+)-catechin, deren herstellung und verwendung sowie diese salze enthaltende pharmazeutische zubereitungen.
DE69414720T2 (de) Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung
DE69030616T2 (de) Pharmazeutische Zusammensetzungen zur Hemmung der Maillardreaktion
DE69412760T2 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
DE2945790C2 (de) Neutrales L-Ornithin-L-malat-dihydrat und neutrales L-Lysin-L-malat-monohydrat und Verfahren zu deren Herstellung
EP0806955B1 (de) Enrofloxacin-injektions- oder infusionslösungen
DE2721171A1 (de) Neues vincaminsalz, seine herstellung und es enthaltende pharmazeutische zubereitungen
DE69730902T2 (de) Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
DE2433407A1 (de) Sulfate von hydroxyaethylstaerke
DE69519463T2 (de) N-morpholino-n-nitrosaminoacetonitril-cyclodextrin-einschlussverbindungen
DE2515001C2 (de) Prostaglandin enthaltende gefriergetrocknete Pulver
DE60217899T2 (de) Einschlusskomplex von taxol mit 2-hydroxypropyl-beta-cyclodextrin
DE3740588C2 (de) Temperaturstabiles Breitband-Antibiotikum
DE69124609T2 (de) Verfahren zur Reinigung von komerziellen Karraghenanen
EP0490193A1 (de) Komplexe des aktiven Enantiomers des Ibuprofens mit Cyclodextrin
DE2920020C2 (enrdf_load_stackoverflow)
AT395943B (de) Pharmazeutische waessrige formulierungen, die ein piperidinylcyclopentylheptensaeure-derivat enthalten
DE3119510C2 (enrdf_load_stackoverflow)
EP0046506B1 (de) Vincamin-saccharinat und dieses enthaltende Arzneimittel
DE69016087T2 (de) Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
DE69417169T2 (de) Antineoplastische pharmazeutische Zusammensetzung enthaltend ein Fumagillolderivat und einen Platinkomplex
AT392904B (de) Verfahren zur herstellung einer zur oralen verabreichung von etoposid bestimmten weichgelantinekapsel

Legal Events

Date Code Title Description
PL Patent ceased